NEW YORK (GenomeWeb News) – Genisphere said today it has licensed its 3DNA Signal Amplification technology to Chembio Diagnostics.

Quest Diagnostics has been awarded US Patent No. 8,346,485, "Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction."

Genisphere and the Lankenau Institute for Medial Research said this week that they are expanding their collaboration on the development of microRNA biomarkers for ulcerative colitis to include Crohn's disease and other inflammatory bowel disorders.

NEW YORK (GenomeWeb News) –Genisphere and the Lankenau Institute for Medical Research today said that they have expanded their research collaboration aimed at identifying microRNA biomarkers to include Crohn's Disease and other inflammatory bowel disorders.

Hahn-Schickard-Gesellschaft of Villingen-Schwenningen, Germany, has received US Patent No.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Affymetrix plans to offer Genisphere's miRNA reagents for use with its GeneChip miRNA 2.0 Arrays under a new license agreement, Affy said today.

Genisphere said this week that it has signed deals licensing its RNA target amplification and FlashTag Biotin microRNA labeling technologies to Affymetrix.

Quest Diagnostics, Albert Einstein College of Medicine, Riken, Genisphere, Stanford, DNA Electronics, US Genomics, Qiagen, and others awarded US patents.


Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.